http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2741196-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d6178cfa91950d9b89c112c84f476a7a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61H9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61H19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B17-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F5-41 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-16 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61H19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61H9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F5-41 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B17-22 |
| filingDate | 2020-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7cb37bcf358897a7012ad95ea1cb799f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb8c8973e8e9f901e07404440a069dbd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f64c3112e9960f2f76090e009615efc4 |
| publicationDate | 2021-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2741196-C2 |
| titleOfInvention | Method of treating peyronie's disease |
| abstract | FIELD: medicine. n SUBSTANCE: invention relates to medicine, specifically to urology. In Peyronie's disease (PD), platelet enriched growth factor autoplasma (PEA) is injected into the penis (P), fibrosis and/or calcified plaques on all sides - once week for 6 weeks. In PD with deviation of penis for more than 30° for 6 weeks, 2 procedures are performed on a weekly basis, the first one involves PEA injections into a penis, a fibrosis zone and/or calcified plaques on all sides, a LNP-therapy for penis 5–10 minutes, the second is LNP-therapy for 5–10 minutes on penis. Other variant of the therapy with PD with deviation of penis for more than 30° for 6 weeks is followed by 2 weekly procedures, the first one involves a session of extracorporeal shock-wave therapy (ESWT) on the penis, a fibrosis zone and/or calcinated plaques in amount of 4000 strokes, PEA injections in penis, a fibrosis zone and/or calcified plaques on all sides; thereafter, ESWT is performed in volume of 1000 beats at the PEA injection points, the second one is the ESWT on a penis, a fibrosis zone and/or calcified plaques in amount of 4000 beats. In PD with marked deviation of penis for 2 weeks, 2 procedures are performed on a weekly basis. In the first one, a ESWT session is performed on a penis, a fibrosis zone and/or calcified plaques in volume of 4000 strokes, PEA injections into the penis, a fibrosis zone and/or calcified plaques on all sides, after which ESWT is made in volume of 1000 beats at the PEA injection points. That is followed by 5–10-minute therapy on the penis. Second procedure involves ESWT on a penis, a fibrosis zone and / or calcified plaques in amount of 4000 beats. That is followed by 5–10-minute therapy on the penis. If PD is combined with erectile dysfunction (ED) for 6 weeks, PEA is injected weekly into a penis, a fibrosis and/or calcified plaques on all sides, muscles involved in the act of erection, once week for 6 weeks. From the first day of treatment, administration of type 5 phosphodiesterase (PDE-5) inhibitors 5 mg/day for 6 weeks is prescribed daily. If PD is combined with erectile dysfunction (ED) with deviation of penis of more than 30° for 6 weeks, 2 procedures are performed on a weekly basis. First session involves an ESWT session on a penis, a fibrosis zone and/or calcified plaques, muscles participating in an erection act in amount of 6000 strokes. That is followed by injections of PEA into a penis, a fibrosis zone and/or calcified plaques on all sides, muscles participating in an act of erection, followed by performing ESWT in volume of 1000 strokes at PEA insertion points. From the first day of treatment PDE-5 inhibitors 5 mg/day for 6 weeks are prescribed daily. Into the second procedure, ESWT is applied to a penis, a fibrosis zone and/or calcified plaques, muscles participating in an erection act in volume of 6000 strokes. Another treatment option for PD-ED combination with penis deviation of more than 30° for 6 weeks is followed by 2 procedures on a weekly basis. PEA is injected into a penis, a fibrosis zone and/or calcified plaques on all sides, into muscles involved in the act of erection. Then the LNP-therapy on penis is performed for 5–10 minutes. From the first day of treatment PDE-5 inhibitors 5 mg/day for 6 weeks are prescribed daily. Second procedure is followed by a laser therapy for 5–10 minutes on the penis. In PD with ED with pronounced penis deviation within 6 weeks, 2 procedures are performed on a weekly basis. First procedure involves a session of ESWT on a penis, a fibrosis zone and/or calcified plaques, muscles involved in an act of erection, in amount of 6000 strokes. That is followed by injecting PEA into a penis, a fibrosis zone and/or calcified plaques on all sides, muscles involved in an erection, followed by ESWT in volume of 1000 beats at PEA insertion points. That is followed by 5-to-10-minute LNP therapy on a penis. From the first day of treatment PDE-5 inhibitors 5 mg/day for 6 weeks are prescribed daily. Into the second procedure, ESWT is applied to a penis, a fibrosis zone and/or calcified plaques, muscles participating in an erection act in volume of 6000 strokes. That is followed by 5–10 minute therapy on the penis. n EFFECT: method enables pathogenetic treatment of Peyronie's disease in men by stimulating cell proliferation, formation of vessels, increasing amount of type I collagen, remodeling of cell matrix, inhibition of fibrosis process, as well as reducing or suppressing inflammatory reaction and pain syndrome. n 1 cl, 2 ex |
| priorityDate | 2020-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 138.